Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Share:
Related MRK
Big Business Delivers Christmas Wish List To Trump, 10 Months Early
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially Blockbuster Drug Candidates Offers Significant Upside (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2017GuggenheimUpgradesNeutralBuy
Jan 2017Morgan StanleyUpgradesEqual-WeightOverweight
Dec 2016JefferiesDowngradesHoldUnderperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!